427 related articles for article (PubMed ID: 29921698)
1. Computational Characterization of Suppressive Immune Microenvironments in Glioblastoma.
Luoto S; Hermelo I; Vuorinen EM; Hannus P; Kesseli J; Nykter M; Granberg KJ
Cancer Res; 2018 Oct; 78(19):5574-5585. PubMed ID: 29921698
[TBL] [Abstract][Full Text] [Related]
2. Analysis of immunobiologic markers in primary and recurrent glioblastoma.
Rahman M; Kresak J; Yang C; Huang J; Hiser W; Kubilis P; Mitchell D
J Neurooncol; 2018 Apr; 137(2):249-257. PubMed ID: 29302887
[TBL] [Abstract][Full Text] [Related]
3. Immune microenvironments differ in immune characteristics and outcome of glioblastoma multiforme.
Zhang B; Shen R; Cheng S; Feng L
Cancer Med; 2019 Jun; 8(6):2897-2907. PubMed ID: 31038851
[TBL] [Abstract][Full Text] [Related]
4. IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.
Barresi V; Simbolo M; Mafficini A; Martini M; Calicchia M; Piredda ML; Ciaparrone C; Bonizzato G; Ammendola S; Caffo M; Pinna G; Sala F; Lawlor RT; Ghimenton C; Scarpa A
Acta Neuropathol Commun; 2021 Dec; 9(1):200. PubMed ID: 34952640
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of an anoikis-associated gene signature to predict clinical character, stemness, IDH mutation, and immune filtration in glioblastoma.
Sun Z; Zhao Y; Wei Y; Ding X; Tan C; Wang C
Front Immunol; 2022; 13():939523. PubMed ID: 36091049
[TBL] [Abstract][Full Text] [Related]
6. Genomic Characterization of Six Virus-Associated Cancers Identifies Changes in the Tumor Immune Microenvironment and Altered Genetic Programs.
Varn FS; Schaafsma E; Wang Y; Cheng C
Cancer Res; 2018 Nov; 78(22):6413-6423. PubMed ID: 30254145
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation.
Jha P; Pia Patric IR; Shukla S; Pathak P; Pal J; Sharma V; Thinagararanjan S; Santosh V; Suri V; Sharma MC; Arivazhagan A; Suri A; Gupta D; Somasundaram K; Sarkar C
Neuro Oncol; 2014 Dec; 16(12):1607-17. PubMed ID: 24997139
[TBL] [Abstract][Full Text] [Related]
8. RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
Bagley SJ; Hwang WT; Brem S; Linette GP; O'Rourke DM; Desai AS
J Neurooncol; 2019 Jan; 141(1):95-102. PubMed ID: 30353265
[TBL] [Abstract][Full Text] [Related]
9. A machine learning classifier trained on cancer transcriptomes detects NF1 inactivation signal in glioblastoma.
Way GP; Allaway RJ; Bouley SJ; Fadul CE; Sanchez Y; Greene CS
BMC Genomics; 2017 Feb; 18(1):127. PubMed ID: 28166733
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive analysis of Reverse Phase Protein Array data reveals characteristic unique proteomic signatures for glioblastoma subtypes.
Patil V; Mahalingam K
Gene; 2019 Feb; 685():85-95. PubMed ID: 30401645
[TBL] [Abstract][Full Text] [Related]
11. Association of Isocitrate Dehydrogenase (IDH) Status With Edema to Tumor Ratio and Its Correlation With Immune Infiltration in Glioblastoma.
Dubinski D; Won SY; Rauch M; Behmanesh B; Ngassam LDC; Baumgarten P; Senft C; Harter PN; Bernstock JD; Freiman TM; Seifert V; Gessler F
Front Immunol; 2021; 12():627650. PubMed ID: 33868245
[TBL] [Abstract][Full Text] [Related]
12. Establishment and validation of an immune-based prognostic score model in glioblastoma.
Qin Z; Zhang X; Chen Z; Liu N
Int Immunopharmacol; 2020 Aug; 85():106636. PubMed ID: 32534425
[TBL] [Abstract][Full Text] [Related]
13. Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups.
Hinrichs BH; Newman S; Appin CL; Dunn W; Cooper L; Pauly R; Kowalski J; Rossi MR; Brat DJ
Acta Neuropathol Commun; 2016 Jan; 4():4. PubMed ID: 26757882
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival.
Dejaegher J; Solie L; Hunin Z; Sciot R; Capper D; Siewert C; Van Cauter S; Wilms G; van Loon J; Ectors N; Fieuws S; Pfister SM; Van Gool SW; De Vleeschouwer S
Neuro Oncol; 2021 Feb; 23(2):240-250. PubMed ID: 33130898
[TBL] [Abstract][Full Text] [Related]
15. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
16. Unveiling divergent treatment prognoses in IDHwt-GBM subtypes through multiomics clustering: a swift dual MRI-mRNA model for precise subtype prediction.
Ji Q; Zheng Y; Zhou L; Chen F; Li W
J Transl Med; 2024 Jun; 22(1):578. PubMed ID: 38890658
[TBL] [Abstract][Full Text] [Related]
17. Construction of Interferon-Gamma-Related Gene Signature to Characterize the Immune-Inflamed Phenotype of Glioblastoma and Predict Prognosis, Efficacy of Immunotherapy and Radiotherapy.
Ji H; Ba Y; Ma S; Hou K; Mi S; Gao X; Jin J; Gong Q; Liu T; Wang F; Liu Z; Li S; Du J; Hu S
Front Immunol; 2021; 12():729359. PubMed ID: 34566988
[TBL] [Abstract][Full Text] [Related]
18. Expression profiling of single cells and patient cohorts identifies multiple immunosuppressive pathways and an altered NK cell phenotype in glioblastoma.
Close HJ; Stead LF; Nsengimana J; Reilly KA; Droop A; Wurdak H; Mathew RK; Corns R; Newton-Bishop J; Melcher AA; Short SC; Cook GP; Wilson EB
Clin Exp Immunol; 2020 Apr; 200(1):33-44. PubMed ID: 31784984
[TBL] [Abstract][Full Text] [Related]
19. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
20. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
